Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
Go back to Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 110.40 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $110.40 | 52 Week High | $18.39 | |||
| Open | $110.40 | 52 Week Low | $6.96 | |||
| Day High | $110.40 | P/E | N/A | |||
| Day Low | $110.40 | EPS | $-0.58 | |||
| Volume | 78,538 | |||||
